The regulator agreed to allow Sangamo Therapeutics to use data to seek accelerated approval for its Fabry gene therapy ...

Sangamo's phase 1/2 STARR study data using isaralgagene civaparvovec targeting patients with Fabry Disease is expected in H1 2025. Learn more on SGMO stock here.

Shares in Sangamo Therapeutics (Nasdaq: SGMO) surged around 40% on Tuesday, following the announcement that the US Food and ...

Yale spinout Modifi agreed to sell to Merck for $30 million upfront. Elsewhere, Sangamo plotted a much faster path to market ...

Sangamo Therapeutics, Inc. engages in researching and developing transcription factors in the regulation of genes. It focuses on the research, development and commercialization of engineered ...

Truist Financial analyst Nicole Germino maintained a Hold rating on Sangamo Biosciences (SGMO – Research Report) today. The ...

Using a gene signature technique to tailor chemotherapy for patients with early triple negative breast cancer shows promise ...

By squeezing Regeneron’s Eylea, eye disease drug Vabysmo has become one of the biggest growth drivers for Roche. | Despite ...

Ipsen has reported strong Q3 2024 results, with sales reaching 837 million euros ($884 million), an 8.6% year-on-year ...

A team of scientists has discovered surprising connections among gene activity, genome packing, and genome-wide motions, ...

Genetic tests showed that certain patients were predisposed to brain injuries if they took the drugs. That information ...

Scientists at the Icahn School of Medicine at Mount Sinai, in collaboration with colleagues in the field, have developed an ...